ES2479543T1 - Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas - Google Patents

Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas Download PDF

Info

Publication number
ES2479543T1
ES2479543T1 ES10768496.1T ES10768496T ES2479543T1 ES 2479543 T1 ES2479543 T1 ES 2479543T1 ES 10768496 T ES10768496 T ES 10768496T ES 2479543 T1 ES2479543 T1 ES 2479543T1
Authority
ES
Spain
Prior art keywords
preparation
methods
cell populations
immunoregulatory activity
immunoregulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES10768496.1T
Other languages
English (en)
Other versions
ES2479543T3 (es
Inventor
Dirk Buescher
Olga De La Rosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Cellerix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellerix SA filed Critical Cellerix SA
Publication of ES2479543T1 publication Critical patent/ES2479543T1/es
Application granted granted Critical
Publication of ES2479543T3 publication Critical patent/ES2479543T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para la preparación y/o generación de células inmunomoduladoras que comprende poner en contacto una población celular de células madre mesenquimatosas (MSC) y/o fibroblastos con leucocitos de sangre periférica durante entre aproximadamente 2 horas y aproximadamente 25 días.

Claims (1)

  1. imagen1
    imagen2
ES10768496.1T 2009-10-23 2010-10-22 Poblaciones de células que presentan actividad inmunorreguladora, métodos para la preparación y usos de las mismas Active ES2479543T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918615.6A GB0918615D0 (en) 2009-10-23 2009-10-23 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
GB0918615 2009-10-23
PCT/EP2010/066007 WO2011048222A1 (en) 2009-10-23 2010-10-22 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Publications (2)

Publication Number Publication Date
ES2479543T1 true ES2479543T1 (es) 2014-08-20
ES2479543T3 ES2479543T3 (es) 2018-04-17

Family

ID=41426608

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10768496.1T Active ES2479543T3 (es) 2009-10-23 2010-10-22 Poblaciones de células que presentan actividad inmunorreguladora, métodos para la preparación y usos de las mismas

Country Status (6)

Country Link
US (1) US9969976B2 (es)
EP (1) EP2491115B1 (es)
JP (1) JP2013507945A (es)
ES (1) ES2479543T3 (es)
GB (1) GB0918615D0 (es)
WO (1) WO2011048222A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515258A (ja) * 2011-05-19 2014-06-30 ティゲニックス エス．エー．ユー 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
ES2434853B1 (es) * 2012-06-12 2014-09-30 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos
ES2906161T3 (es) * 2015-06-03 2022-04-13 Aelan Cell Tech Inc Métodos complementarios para terapias basadas en IL-2 y terapias basadas en células madre mesenquimales
US11291689B2 (en) 2015-06-03 2022-04-05 Aelan Cell Technologies, Inc. Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
US20230151329A1 (en) * 2019-10-15 2023-05-18 Figene, Llc Fibroblast-based immunotherapy of graves disease
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
AU2005228442A1 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory T cells and uses thereof
JP2006280307A (ja) 2005-04-01 2006-10-19 Kyoto Univ 制御性ｔ細胞の製造方法
EP1926813B2 (en) * 2005-09-23 2019-05-22 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
GB0820397D0 (en) * 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Also Published As

Publication number Publication date
US9969976B2 (en) 2018-05-15
WO2011048222A1 (en) 2011-04-28
ES2479543T3 (es) 2018-04-17
GB0918615D0 (en) 2009-12-09
EP2491115A1 (en) 2012-08-29
EP2491115B1 (en) 2018-01-03
US20130052174A1 (en) 2013-02-28
JP2013507945A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
ES2479543T1 (es) Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
ES2660204T3 (es) Método de reparación tisular
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
RU2012105922A (ru) Дифференцирование человеческих эмбриональных стволовых клеток
AR095541A1 (es) Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras
PH12018500371A1 (en) Clinical formulations
CL2011002816A1 (es) Metodo y aparato para reducir una materia prima solida que comprende disponer dicha materia prima sobre elementos con superficies catodicas de un conjunto de celdas bipolares dentro de un alojamiento, hacer circular sal fundida para que entre en contacto con los elementos y la materia prima y aplicar un potencial electrico.
RU2013110524A (ru) Лечение диабета при помощи панкреатических эндокринных клеток-предшественников
EP2444483A3 (en) Materials and methods relating to cell based therapies
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
BRPI0417194A (pt) células-tronco
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
ES2190727B1 (es) Dispositivo para formar y/o aumentar el numero relativo de celulas indiferenciadas en una poblacion celular y procedimientos correspondientes.
CL2012002542A1 (es) Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2.
BR112012022238A2 (pt) pele artificial
MX2016005824A (es) Metodo de cultivo celular.
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.
DE60307615D1 (de) Zellkulturmedium
WO2004108208A3 (en) Methods and apparatus for conversion of eukaryotic cells by application of electric and magnetic fields
ATE374628T1 (de) Milchproteinbiofilm und verwendungen davon